Akademska digitalna zbirka SLovenije - logo
E-viri
  • ω-3 Polyunsaturated Fatty A...
    Del Gobbo, Liana C; Imamura, Fumiaki; Aslibekyan, Stella; Marklund, Matti; Virtanen, Jyrki K; Wennberg, Maria; Yakoob, Mohammad Y; Chiuve, Stephanie E; dela Cruz, Luicito; Frazier-Wood, Alexis C; Fretts, Amanda M; Guallar, Eliseo; Matsumoto, Chisa; Prem, Kiesha; Tanaka, Tosh; Wu, Jason H. Y; Zhou, Xia; Helmer, Catherine; Ingelsson, Erik; Yuan, Jian-Min; Barberger-Gateau, Pascale; Campos, Hannia; Chaves, Paulo H. M; Djoussé, Luc; Giles, Graham G; Gómez-Aracena, Jose; Hodge, Allison M; Hu, Frank B; Jansson, Jan-Håkan; Johansson, Ingegerd; Khaw, Kay-Tee; Koh, Woon-Puay; Lemaitre, Rozenn N; Lind, Lars; Luben, Robert N; Rimm, Eric B; Risérus, Ulf; Samieri, Cecilia; Franks, Paul W; Siscovick, David S; Stampfer, Meir; Steffen, Lyn M; Steffen, Brian T; Tsai, Michael Y; van Dam, Rob M; Voutilainen, Sari; Willett, Walter C; Woodward, Mark; Mozaffarian, Dariush

    JAMA internal medicine, 08/2016, Letnik: 176, Številka: 8
    Journal Article

    IMPORTANCE: The role of ω-3 polyunsaturated fatty acids for primary prevention of coronary heart disease (CHD) remains controversial. Most prior longitudinal studies evaluated self-reported consumption rather than biomarkers. OBJECTIVE: To evaluate biomarkers of seafood-derived eicosapentaenoic acid (EPA; 20:5ω-3), docosapentaenoic acid (DPA; 22:5ω-3), and docosahexaenoic acid (DHA; 22:6ω-3) and plant-derived α-linolenic acid (ALA; 18:3ω-3) for incident CHD. DATA SOURCES: A global consortium of 19 studies identified by November 2014. STUDY SELECTION: Available prospective (cohort, nested case-control) or retrospective studies with circulating or tissue ω-3 biomarkers and ascertained CHD. DATA EXTRACTION AND SYNTHESIS: Each study conducted standardized, individual-level analysis using harmonized models, exposures, outcomes, and covariates. Findings were centrally pooled using random-effects meta-analysis. Heterogeneity was examined by age, sex, race, diabetes, statins, aspirin, ω-6 levels, and FADS desaturase genes. MAIN OUTCOMES AND MEASURES: Incident total CHD, fatal CHD, and nonfatal myocardial infarction (MI). RESULTS: The 19 studies comprised 16 countries, 45 637 unique individuals, and 7973 total CHD, 2781 fatal CHD, and 7157 nonfatal MI events, with ω-3 measures in total plasma, phospholipids, cholesterol esters, and adipose tissue. Median age at baseline was 59 years (range, 18-97 years), and 28 660 (62.8%) were male. In continuous (per 1-SD increase) multivariable-adjusted analyses, the ω-3 biomarkers ALA, DPA, and DHA were associated with a lower risk of fatal CHD, with relative risks (RRs) of 0.91 (95% CI, 0.84-0.98) for ALA, 0.90 (95% CI, 0.85-0.96) for DPA, and 0.90 (95% CI, 0.84-0.96) for DHA. Although DPA was associated with a lower risk of total CHD (RR, 0.94; 95% CI, 0.90-0.99), ALA (RR, 1.00; 95% CI, 0.95-1.05), EPA (RR, 0.94; 95% CI, 0.87-1.02), and DHA (RR, 0.95; 95% CI, 0.91-1.00) were not. Significant associations with nonfatal MI were not evident per 1 SD. Across quintiles, lower risk of nonfatal MI was evident with EPA (RR, 0.71; 95% CI, 0.56-0.90) and ALA (RR, 0.87; 95% CI, 0.78-0.97), and lower risk of fatal CHD was evident with DPA (RR, 0.76; 95% CI, 0.65-0.90) and DHA (RR, 0.77; 95% CI, 0.64-0.89). Associations appeared generally stronger in phospholipids and total plasma. Restricted cubic splines did not identify evidence of nonlinearity in dose responses. CONCLUSIONS AND RELEVANCE: On the basis of available studies of free-living populations globally, biomarker concentrations of seafood and plant-derived ω-3 fatty acids are associated with a lower incidence of fatal CHD.